Legislation roundup: Pharma, securities disputes and private equity

January 19, 2019 | BY

Susan Mok

Eleven pilot cities will carry out centralized procurement of pharmaceuticals, Shanghai sets up a mechanism for model securities dispute judgments and Zhuhai allows foreign PE firms to raise funds in China

Pharmaceuticals

General Office of the State Council, Plan for the Pilot Project for the Arrangement by the State of the Centralized Procurement and Use of Pharmaceuticals

The state is organizing a pilot project in the 11 municipalities of Beijing, Tianjin, Shanghai, Chongqing, Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu and Xi'an for the centralized procurement and use of pharmaceuticals, selecting the pilot products from generic drugs that have undergone a consistency evaluation of their quality and efficacy.

See the digest for more details.

Further reading

Capital Markets

Shanghai Financial Court, Provisions on the Mechanism for Model Securities Dispute Judgments

A model case is a case among the mass of securities disputes that is representative in terms of the factual points of dispute and legal points of dispute, and the term "parallel case" means a case that has factual points of dispute and legal points of dispute in common with a model case.

In terms of the finding of facts, unless there is evidence to the contrary to overrule, the parties to a parallel case are not required to adduce separate evidence in respect of the facts in common that were found in the model judgment.

See the digest for more details.

Further reading

Private Equity

Zhuhai City, Tentative Measures for the Administration of the Pilot Foreign-invested Equity Investment Enterprise Project

Zhuhai City allows foreign enterprises or individuals to establish foreign-invested equity investment enterprises that raise funds from domestic and foreign investors in a non-public manner to invest in enterprises of non-publicly traded equity.

Further reading

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]